| Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study PM Doraiswamy, RA Sperling, RE Coleman, KA Johnson, EM Reiman, ... Neurology 79 (16), 1636-1644, 2012 | 261 | 2012 |
| First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting N Pandit-Taskar, MA Postow, MD Hellmann, JJ Harding, CA Barker, ... Journal of Nuclear Medicine 61 (4), 512-519, 2020 | 203 | 2020 |
| SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study DD Von Hoff, R Ramanathan, M Borad, D Laheru, L Smith, T Wood, ... Journal of Clinical Oncology 27 (15_suppl), 4525-4525, 2009 | 109 | 2009 |
| Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study T Reid, B Oronsky, J Scicinski, CL Scribner, SJ Knox, S Ning, DM Peehl, ... The Lancet Oncology 16 (9), 1133-1142, 2015 | 101 | 2015 |
| Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review E Borazanci, SZ Millis, R Korn, H Han, CJ Whatcott, Z Gatalica, MT Barrett, ... World journal of gastrointestinal oncology 7 (9), 132, 2015 | 99 | 2015 |
| CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody MD Farwell, RF Gamache, H Babazada, MD Hellmann, JJ Harding, ... Journal of Nuclear Medicine 63 (5), 720-726, 2022 | 90 | 2022 |
| Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b/2 pilot clinical trial GS Jameson, E Borazanci, HM Babiker, E Poplin, AA Niewiarowska, ... JAMA oncology 6 (1), 125-132, 2020 | 70 | 2020 |
| Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients T Reid, S Dad, R Korn, B Oronsky, S Knox, J Scicinski Case reports in oncology 7 (1), 79-85, 2014 | 46 | 2014 |
| Pancreatic cancer—could it be that simple? A different context of vulnerability DD Von Hoff, R Korn, S Mousses Cancer cell 16 (1), 7-8, 2009 | 37 | 2009 |
| Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the ProLog consensus initiative (part 1 … F Ricard, B Cheson, S Barrington, J Trotman, A Schmid, G Brueggenwerth, ... Journal of Nuclear Medicine 64 (1), 102-108, 2023 | 23 | 2023 |
| albumin bound paclitaxel (AP)+ paricalcitol (P)+ cisplatin (C)+ gemcitabine (G)(NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) EH Borazanci, G Jameson, MJ Borad, RK Ramanathan, RL Korn, ... J Clin Oncol 36 (4_suppl), 358, 2018 | 11 | 2018 |
| Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent WL Read, P Rosen, P Lee, S Anthony, R Korn, N Raghunand, B Tseng, ... Journal of Clinical Oncology 27 (15_suppl), 3569-3569, 2009 | 11 | 2009 |
| Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the PRoLoG consensus initiative (part 2 … F Ricard, S Barrington, R Korn, G Brueggenwerth, J Trotman, B Cheson, ... Journal of Nuclear Medicine 64 (2), 239-243, 2023 | 9 | 2023 |
| Comparative analysis of three-dimensional volume rendering and maximum intensity projection for preoperative planning in liver cancer JL Ho, A Konda, J Rahman, E Harris, R Korn, A Sabir, B Bawany, R Gulati, ... European Journal of Radiology Open 7, 100259, 2020 | 8 | 2020 |
| 594 A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of LY2940680, an oral Smo inhibitor J Bendell, G Weiss, J Infante, R Ramanathan, S Jones, R Korn, H Burris, ... European Journal of Cancer, 182, 2012 | 8 | 2012 |
| Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients A Ocean, M Noel, A Wang-Gillam, S Chawla, V Chung, S Pant, R Korn, ... Annals of Oncology 30, v275, 2019 | 7 | 2019 |
| Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers M Beeram, E Hamilton, MB Murphy, D Hausman, JR Infante, R Korn, ... Annals of Oncology 28, v82, 2017 | 7 | 2017 |
| Systems Pharmacology Based Biomarker Potentially Predicts Clinical Anti-Cancer Activity of MM-398, Nanoliposomal Irinotecan, nal-IRI J Kim, R Korn, G Fetterly, J Sachdev, N Raghunand, J Prey, K Clark, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 41, S28-S28, 2014 | 7 | 2014 |
| In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr] Zr-Df-IAB22M2C PET/MRI J Schwenck, D Sonanini, D Seyfried, W Ehrlichmann, G Kienzle, ... Theranostics 13 (8), 2408, 2023 | 6 | 2023 |
| Therapeutic potential of targeting amino acid metabolism in pancreatic cancer M Fernandez-Zapico, DW Kim, P Philip, A Vandell, J Eckard, R Korn, ... Cancer Res 79 (suppl 24), B15, 2019 | 6 | 2019 |
